CMEology

CMEology

Overview

With over 25 years in developing continuing education activities, we know how to engage health care providers. At CMEology, our ideas begin and end with the patient. Our activities embrace the National Quality Strategy and are designed to improve the effectiveness of patient care. We strive to provide meaningful learning experiences that inspire and empower. Our outcomes include quantitative assessments with descriptive statistics and subgroup analyses, qualitative results, and outcomes impact analysis and modeling.


Challenging Cases in the Management of Bipolar Depression: What Would You Do?

Bipolar depression affects a wide range of patient populations who can sometimes present unique clinical challenges. Bipolar depression occurs across the spectrum of age from young to old, in those with mixed features, and in patients with comorbidities. Given the heterogeneity of bipolar depression presentations, there is no universal approach to its management, and clinicians face numerous cha...
CMEology

Clinical Case Challenges: Evidence-Based Strategies in the Diagnosis and Management of Bipolar Depression

Primary care is frequently the first point of contact for individuals with bipolar depression. Although bipolar depression is often diagnosed and managed by psychiatrists, access to psychiatrists can be a limiting factor to care delivery. In one study, fewer than half of patients referred from primary care scheduled an appointment with a psychiatrist, and fewer than half of scheduled visits were...
CMEology

OFF to ON: Strategies to Manage OFF Episodes in Patients with Parkinson’s disease

This activity will feature a patient with Parkinson’s disease (PD) who has been experiencing progressive OFF episodes that are not responding to conventional therapeutic strategies and are having a negative impact on his activities of daily living and quality of life. The activity will review information that community neurologists need to know about PD motor fluctuations, including clinical m...
CMEology

Pharmacologic Treatment of ADPKD: Monitoring and Risk Mitigation

The advent of pharmacologic therapy for ADPKD offers new opportunities to delay the progression of renal decline for patients. However, health care providers need to know how to identify patients at high risk of progression when considering therapy and how to manage patients receiving disease-modifying therapy. This is the third of three related activities on the pharmacologic management of ...
CMEology

Pharmacologic Treatment of ADPKD: Patient Selection and Individualization

The advent of pharmacologic therapy for ADPKD offers new opportunities to delay the progression of renal decline for patients. However, health care providers need to know how to identify patients at high risk of progression when considering therapy and how to manage patients receiving disease-modifying therapy. This is the first of three related activities on the pharmacologic management of ...
CMEology

Pharmacologic Treatment of ADPKD: Successful Initiation of Pharmacologic Therapy for ADPKD

The advent of pharmacologic therapy for ADPKD offers new opportunities to delay the progression of renal decline for patients. However, health care providers need to know how to identify patients at high risk of progression when considering therapy and how to manage patients receiving disease-modifying therapy. This is the second of three related activities on the pharmacologic management of...
CMEology

Setting the Stage for MDD Recovery: Strategies for the Busy Primary Care Provider

In the United States, most adults with major depressive disorder (MDD) are treated by primary care providers (PCPs). Therefore, it is essential that PCPs are adept at using patient-centered care to set the stage for MDD recovery. In particular, PCPs must be prepared to detect and respond to two of the most common threats to recovery: residual MDD symptoms and intolerable side effects of antidepr...
CMEology

Strategies for Neuroprotection, Relapse Prevention, and Mortality Reduction in Patients with Schizophrenia

Only a minority of patients with schizophrenia consistently adhere to their oral antipsychotics. Long-acting injectable (LAI) formulations of antipsychotics improve patient outcomes through both neuroprotection and improved adherence. To ensure that more patients with schizophrenia are offered the opportunity to take LAIs, clinicians who provide psychiatric care must possess accurate information...
CMEology

Strategies to Improve Management of ADPKD: Navigating Pitfalls and Overcoming Challenges

Although the most common inherited renal disorder, autosomal dominant polycystic kidney disease (ADPKD) is often underdiagnosed and undertreated. Nephrologists report that ADPKD is associated with the highest unmet need among renal diseases. Unmet needs for the optimal care of patients with ADPKD include improved management of renal and extrarenal manifestations and recognition of genetic factor...
CMEology

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map